UBS Group
IRWD icon

UBS Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-107,460
Closed -$1.44M – 8667
2015
Q1 		$1.44M Buy
+107,460
New +$1.41M ﹤0.01% 3232

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's IRWD Position: Q2 2026 in Review

UBS Group reduced its Ironwood Pharmaceuticals (IRWD) stake by 58% in Q2 2026, selling an estimated $2.1M and leaving 389,529 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5292.

UBS Group first reported a position in IRWD in Q4 2014 and has held it in 47 quarters since. The position peaked at $26.4M in Q1 2024. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • UBS Group held 389,529 shares of Ironwood Pharmaceuticals worth $1.64M as of Q2 2026.
  • UBS Group sold 543,696 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5292 holding.
  • UBS Group first reported a position in Ironwood Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Ironwood Pharmaceuticals position peaked at $26.4M in Q1 2024.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.